The Emperor of All Maladies

Farber discovered advertising before science. After his antifolate work, Farber teamed with Mary Lasker, a Manhattan socialite and advertising genius, to transform cancer from a whispered-about shame into a national cause. They invented Jimmy, a poster child with lymphoma, and raised money through radio broadcasts and baseball players. A disease needed icons, slogans, and mascots to attract funding.

The Laskerites engineered the War on Cancer. Through relentless lobbying, a full-page 1969 New York Times ad addressed to Nixon, and an Ann Landers column that buried the Senate in a million letters, they pushed the 1971 National Cancer Act through Congress, unlocking roughly 1.5 billion dollars over three years. Cancer research funding, once less than what Americans spent on a football afternoon, became a national priority.

Halsted's logic seemed unassailable. William Halsted believed cancer spread outward like a pinwheel from a central point, so cutting wider and deeper must cure more. His radical mastectomy removed the breast, chest muscles, lymph nodes, and sometimes ribs and collarbone, leaving women permanently disfigured. Surgeons escalated to superradical and ultraradical operations for nearly a century.

The theory was fatally flawed. If a cancer was truly local, a smaller operation cured it just as well. If it had already spread microscopically, no amount of cutting helped. Halsted's own 1907 data showed survival depended on how far cancer had spread before surgery, not surgical aggressiveness. Yet it took until Bernard Fisher's 1981 randomized trial of 1,765 women to prove statistically that radical mastectomy offered no survival benefit over simpler surgery.

Combination chemotherapy was borrowed from tuberculosis. At the National Cancer Institute in the late 1950s, Emil Frei and Emil Freireich reasoned that single drugs failed because cancer grew resistant, just as bacteria did to lone antibiotics. Howard Skipper's mouse studies showed each drug dose killed a fixed percentage of cells, so relentless, repeated, multi-drug assault was needed.

VAMP nearly killed patients before saving them. Their four-drug regimen (vincristine, amethopterin, mercaptopurine, prednisone) was so toxic colleagues called the leukemia ward a butcher shop. Children crashed into near-fatal states, then their marrows regenerated cancer-free. When leukemia relapsed in the brain, a protected sanctuary drugs couldn't reach, Donald Pinkel added spinal injections and skull radiation. His total therapy pushed cure rates for childhood ALL toward 80 percent.

Cancer is ancient but was long invisible. A 4,000-year-old Egyptian papyrus describes breast tumors and, under treatment, records only there is none. A Chiribaya mummy from Peru carries a thousand-year-old bone tumor. Yet cancer barely appears in ancient medical texts, which teem with descriptions of plague, tuberculosis, and dropsy.

Longevity unmasked cancer. Cancer becomes common only when all other killers have been killed. In most ancient societies, people died young of infection, childbirth, or famine, long before mutations could accumulate. A woman's breast cancer risk rises from 1 in 400 at thirty to 1 in 9 at seventy. Better detection and the near-elimination of infectious disease didn't cause the cancer epidemic; they revealed one that had always been waiting.

The hunt started with a chicken virus. Peyton Rous found a virus causing sarcoma in chickens in 1910, suggesting cancer was infectious. Decades later, Harold Varmus and J. Michael Bishop made the pivotal discovery: the cancer-causing gene in the virus, called src, was not foreign at all. It was a corrupted copy of a normal gene present in all animal cells, from birds to humans.

Two gene types drive cancer. Proto-oncogenes are normal growth accelerators; when mutated into oncogenes, they jam the accelerator on. Tumor suppressor genes are the brakes; when both copies are knocked out, as Alfred Knudson deduced for retinoblastoma with his two-hit hypothesis, the brakes fail. Carcinogens like soot, radiation, and tobacco cause cancer precisely by mutating these endogenous genes.

Ubiquity masked the carcinogen. By the 1940s, four out of five men smoked, so linking tobacco to lung cancer was, as epidemiologist Richard Peto quipped, like asking whether sitting causes cancer. Statistical detection works best at the margins, when a rare exposure meets a rare disease, as when Percivall Pott linked chimney soot to scrotal cancer in 1775.

It took new epidemiological tools. Richard Doll and Austin Bradford Hill's case-control and prospective studies, following tens of thousands of British doctors, proved the link definitively. The 1964 Surgeon General's report followed. Yet the tobacco industry fought back with a masterful strategy: manufacture doubt, fund more research to imply the question was open, and shift the fight to a friendlier Congress rather than face regulators.

Screening is riddled with statistical traps. Finding a small tumor feels obviously good, but the book dismantles this intuition. Lead-time bias makes screened patients appear to survive longer simply because their cancer was found earlier, even if they die at the exact same moment. Overdiagnosis catches harmless tumors that would never have killed; underdiagnosis misses lethal ones.

Mammography's benefit is real but modest and age-dependent. After nine trials spanning decades, the pooled Swedish data showed mammography reduced breast cancer mortality by 20 to 30 percent in women aged 55 to 70, but showed little benefit under 55. As statistician Donald Berry put it, screening is a lottery where a minority win and most pay in time, anxiety, and false alarms. Size matters, but a small tumor can be genetically vicious and a large one benign.

Targeted therapy fulfilled Ehrlich's dream. Chronic myeloid leukemia is driven by a single fused gene, Bcr-abl, producing a hyperactive kinase that forces cells to divide. Brian Druker and chemists at Ciba-Geigy developed a molecule, Gleevec, that slots precisely into the kinase and shuts it off. In the first trial, 53 of 54 patients achieved remission within days, with minimal side effects.

It broke a psychological barrier. Bruce Chabner compared it to Roger Bannister's four-minute mile: what Gleevec shattered was not a limit but the idea of limits. Herceptin, targeting the Her-2 gene in aggressive breast cancer, followed the same logic. These drugs validated attacking cancer's specific molecular vulnerabilities rather than carpet-bombing all dividing cells. CML went from a fatal disease to one patients live with for thirty years.

Sequencing revealed organized chaos. Bert Vogelstein's team mapped the mutations in real tumors. A single breast cancer might carry 50 to 80 mutated genes; one 43-year-old's tumor had 127. No two tumors, even of the same type, share an identical mutation set. Physiological heterogeneity turned out to be genetic heterogeneity.

Beneath the chaos lies order. Most mutations are passengers, along for the ride and inconsequential. A minority are drivers that actually fuel the cancer. When Vogelstein grouped drivers by the biological pathways they disrupt, tumors typically dysregulated only 11 to 15 core pathways, averaging thirteen. Different genes might be broken in different patients, but the same handful of signaling cascades (like the Ras pathway) recur. This finite number offers hope: therapy may need to target pathways, not every individual mutation.

A cure may be biologically impossible. Because cancer arises from the same genes that drive normal growth, aging, and healing, we cannot fully rid ourselves of it without disabling life itself. Mutations accumulate not just from carcinogens but from random copying errors every time a cell divides. Cancer is, in a sense, the terminus of our own development as organisms.

A humbler goal is achievable. Richard Doll's aphorism, mounted above his Oxford office, reframes the mission: death in old age is inevitable, death before old age is not. The realistic win is stretching the cat-and-mouse game of treatment, resistance, and re-treatment longer and longer, converting fatal cancers into manageable chronic conditions, as happened with CML and multiple myeloma. Mukherjee's thought experiment following Queen Atossa across 4,000 years shows survival gains are real but wildly uneven across cancer types.